The Direct III Post Market Study
NCT02693158 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 440
Last updated 2020-06-26
Summary
The primary objective of this multicenter, single-arm, observational study is to evaluate the feasibility of a systematic direct stenting strategy with the Svelte SLENDER IDS Sirolimus-Eluting Coronary Stent-on-a-Wire Integrated Delivery System (SLENDER IDS) in an all-comers, real-world population.
Conditions
Sponsors & Collaborators
-
Svelte Medical Systems, Inc.
lead INDUSTRY
Principal Investigators
-
Dennis Donohoe, MD · Svelte Medical
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-09-30
- Primary Completion
- 2019-01-31
- Completion
- 2020-01-31
Countries
- Netherlands
Study Locations
More Related Trials
-
PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease
NCT03168776 ·Status: COMPLETED ·Phase: NA
-
Treatment of Coronary In-stent Restenosis (ISR) by a Sirolimus Coated or a Paclitaxel Coated Balloon
NCT03242096 ·Status: COMPLETED ·Phase: NA
-
OPtimal stEnt Deployment stRategy oF Contemporary sTents - Registry to Evaluate Percutaneous Coronary Intervention Using Bioresorbable Scaffolds With Thinner-strut Construction and Guidance by intracOronary Imaging to REduce Scaffold Failure
NCT06919562 ·Status: RECRUITING
-
Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III (LONG-DES-III)
NCT01078038 ·Status: COMPLETED ·Phase: PHASE4
-
DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity in an All Comers Population
NCT01331707 ·Status: COMPLETED ·Phase: PHASE4
-
The Intra-Drug Eluting Stent (DES) Restenosis Study
NCT00323895 ·Status: COMPLETED ·Phase: PHASE4
-
FIM-NL - First-in-Man Study (Netherlands Part) With Sirolimus Coated Modified BX Velocity Stent
NCT00233818 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Virtue® SAB in the Treatment of Coronary ISR Trial
NCT07045194 ·Status: RECRUITING ·Phase: NA
-
The Medtronic Endeavor III Drug Eluting Coronary Stent System Clinical Trial
NCT00217256 ·Status: COMPLETED ·Phase: NA
-
Treatment of Coronary In-Stent Restenosis by a Sirolimus (Rapamycin) Coated Balloon or a Paclitaxel Coated Balloon
NCT02996318 ·Status: COMPLETED ·Phase: NA
-
Vascular Implant Safety and Efficacy Study
NCT03263858 ·Status: COMPLETED ·Phase: NA
-
COronary Native Artery First in Man Investigation of ISA 247 Elution to Prevent Restenotic Mechanisms (CONFIRM 1)
NCT00689767 ·Status: TERMINATED ·Phase: NA
-
Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent
NCT02870140 ·Status: COMPLETED ·Phase: NA
-
OPTIMIZE IDE for the Treatment of ACS
NCT03190473 ·Status: TERMINATED ·Phase: NA
-
Optimal Stent Deployment Strategy of Contemporary Stents
NCT05292651 ·Status: RECRUITING ·Phase: NA
-
Post-marketing Registry of Inspiron Sirolimus Eluting Coronary Stent
NCT03263260 ·Status: COMPLETED
-
Hybrid Sirolimus-eluting Versus Everolimus-eluting Stents for Total Coronary Occlusions
NCT01516723 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of the Orsiro Drug Eluting Stent System
NCT01356888 ·Status: UNKNOWN ·Phase: NA
-
Advapro Coronary Stent System in Coronary Artery Diseased Patients.
NCT06300268 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
The Initial Double-Blind Drug-Eluting Stent vs Bare-Metal Stent Study.
NCT00233805 ·Status: COMPLETED ·Phase: PHASE2
-
The Clinical Evaluation of the Cinatra™ Corolimus-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries
NCT01025869 ·Status: TERMINATED ·Phase: NA
-
Sirolimus- and Paclitaxel-Eluting Stents for Small Vessels (ISAR-SMART-3)
NCT00146575 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy Study of NOYA Sirolimus-Eluting Stent to Treat Coronary Artery Disease
NCT02216058 ·Status: UNKNOWN ·Phase: NA
-
SELUTION 4 De Novo Small Vessel IDE Trial
NCT05946629 ·Status: RECRUITING ·Phase: NA
-
Sirolimus-eluting Stents With Biodegradable Polymer Versus an Everolimus-eluting Stents
NCT01443104 ·Status: COMPLETED ·Phase: NA